Skip to main content

Table 4 Distribution of patients according to risk groups

From: Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study

P < 0.0001 HR 1.98

N = 134

OS Median months [95 % CI]

Risk 0

29

13.2 [9.6 – NR]

Risk 1

50

9.9 [6.7 – 11.8]

Risk 2

34

3.5 [2.7– 6.5]

Risk 3

13

2.4 [1.1 – 6.17]

Missinga

8

 
  1. Patients group Risk 0, 1, 2 or 3: patients having 0, 1, 2 or 3 adverse factor respectively
  2. Prognostic factors: PS ≥ 1, haemoglobin ≤10 g/dl, presence of liver metastasis at baseline
  3. a Patients with at least one missing prognostic factor